Pharmadrug Inc. PHRX
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 57.42% | 36.53% | -66.01% | -92.43% | -91.36% |
| Depreciation & Amortization | 0.83% | 0.55% | -1.91% | -23.40% | -4.50% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.31% | -12.89% | -68.24% | -81.59% | -81.60% |
| Operating Income | 18.31% | 12.89% | 68.24% | 81.59% | 81.60% |
| Income Before Tax | -74.66% | -14.30% | 52.03% | 97.98% | 97.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -74.66% | -14.30% | 52.03% | 97.83% | 97.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -29.65% | -19.31% | -40.37% | -60.51% | -57.41% |
| Net Income | -90.44% | -18.61% | 53.22% | 98.19% | 97.50% |
| EBIT | 18.31% | 12.89% | 68.24% | 81.59% | 81.60% |
| EBITDA | 22.91% | 16.48% | 73.92% | 85.08% | 84.86% |
| EPS Basic | -60.87% | -3.57% | 59.02% | 98.76% | 98.26% |
| Normalized Basic EPS | -58.82% | -10.00% | 48.72% | 84.88% | 83.00% |
| EPS Diluted | -60.87% | -3.57% | 59.02% | 98.76% | 98.26% |
| Normalized Diluted EPS | -58.82% | -10.00% | 48.72% | 84.88% | 83.00% |
| Average Basic Shares Outstanding | 13.32% | 9.25% | 6.21% | 15.82% | 33.87% |
| Average Diluted Shares Outstanding | 13.32% | 9.25% | 6.21% | 15.82% | 33.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |